These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 12370744)
21. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Press MF; Pike MC; Hung G; Zhou JY; Ma Y; George J; Dietz-Band J; James W; Slamon DJ; Batsakis JG Cancer Res; 1994 Nov; 54(21):5675-82. PubMed ID: 7522962 [TBL] [Abstract][Full Text] [Related]
22. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Naidu R; Wahab NA; Yadav M; Kutty MK Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932 [TBL] [Abstract][Full Text] [Related]
23. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482 [TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Sugano S; Mukai K; Tsuda H; Hirohashi S; Furuya S; Shimosato Y; Ebihara S; Takeyama I Laryngoscope; 1992 Aug; 102(8):923-7. PubMed ID: 1353853 [TBL] [Abstract][Full Text] [Related]
25. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A Int J Cancer; 2002 Dec; 102(5):514-8. PubMed ID: 12432555 [TBL] [Abstract][Full Text] [Related]
26. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865 [TBL] [Abstract][Full Text] [Related]
27. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Jimenez RE; Hussain M; Bianco FJ; Vaishampayan U; Tabazcka P; Sakr WA; Pontes JE; Wood DP; Grignon DJ Clin Cancer Res; 2001 Aug; 7(8):2440-7. PubMed ID: 11489824 [TBL] [Abstract][Full Text] [Related]
28. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Gorgoulis VG; Barbatis C; Poulias I; Karameris AM Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234 [TBL] [Abstract][Full Text] [Related]
29. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma. Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452 [TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of erbB-2 gene amplification in bladder cancer. Sauter G; Moch H; Moore D; Carroll P; Kerschmann R; Chew K; Mihatsch MJ; Gudat F; Waldman F Cancer Res; 1993 May; 53(10 Suppl):2199-203. PubMed ID: 8097962 [TBL] [Abstract][Full Text] [Related]
32. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. Chen PC; Yu HJ; Chang YH; Pan CC J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329 [TBL] [Abstract][Full Text] [Related]
33. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577 [TBL] [Abstract][Full Text] [Related]
34. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. Lipponen PK J Pathol; 1995 Feb; 175(2):203-10. PubMed ID: 7738716 [TBL] [Abstract][Full Text] [Related]
35. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203 [TBL] [Abstract][Full Text] [Related]
36. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions. Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577 [TBL] [Abstract][Full Text] [Related]
37. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615 [TBL] [Abstract][Full Text] [Related]
38. Histologic tumor growth pattern is significantly associated with disease-related survival in muscle-invasive transitional cell carcinoma of the urinary bladder. Krüger S; Noack F; Böhle A; Feller AC Oncol Rep; 2004 Sep; 12(3):609-13. PubMed ID: 15289845 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466 [TBL] [Abstract][Full Text] [Related]
40. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors. Erdogan S; Ergin M; Tuncer I Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]